Investor Presentation January 2022

Ⓡ MiSightⓇ 1 day First and only FDA-approved (1) myopia control contact lens Business Highlights Launching Brilliant FuturesTM Myopia Management Program with MiSightⓇ in multiple countries worldwide including the U.S. Sold as a treatment program by practitioners Investing in myopia management globally including in MiSightⓇ Received regulatory approval in China Growth Drivers (3) Works for nearly all myopic children Cuts myopia progression by roughly 59% on average (2) Works at any age a child starts treatment Works for as long as the child wears it There is no rebound if treatment is stopped CooperCompanies Note: (1) MiSight (omafilcon A) daily wear single use Soft Contact Lenses are indicated for the correction of myopic ametropia and for slowing the progression of myopia (nearsightedness) in children with non-diseased eyes, who at the initiation of use are 8-12 years of age and have a refraction of - 0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal. (2) When compared to the children in the control group wearing a single vision 1-day contact lens. (3) As confirmed by our industry-leading, 7-year clinical study of MiSight". 11

View entire presentation